Anti-KIAA1456 Polyclonal Antibody for WB - Q9P272

Core Product Specifications and Parameters

Biological Background: Probable tRNA Methyltransferase 9B (KIAA1456/TRMT9B) Function and Localization

• KIAA1456, also designated TRMT9B, C8orf79, or TRM9L, is a probable tRNA methyltransferase 9B involved in post-transcriptional modification.
• It may catalyze the methylation of wobble uridines in specific arginine and glutamic acid tRNAs, thereby contributing to tRNA processing and translational fidelity.
• TRMT9B functions as a tumor suppressor by promoting the expression of LIN9, a key component of the DREAM complex that regulates cell cycle progression.
• Expression is frequently down-regulated in breast, bladder, colorectal, cervix, and testicular carcinomas, underscoring its tumor-suppressive role.
• The protein is classified as a phosphoprotein and has been identified in proteomics studies, indicating potential regulation by phosphorylation.
• The gene undergoes alternative splicing, which may generate multiple protein isoforms with distinct functional properties.
• Additional keywords from UniProt include Methyltransferase, S-adenosyl-L-methionine, Transferase, tRNA processing, and Reference proteome, highlighting its enzymatic and biological significance.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide spanning amino acids 150–250; this internal region may enable detection of both full-length and shorter isoforms under denaturing and native conditions.
• The product specification indicates a protein weight of 14 kDa, but the UniProt-predicted molecular mass is approximately 51 kDa; validate the observed band size using appropriate positive cell or tissue lysates.
• Optimize antibody dilution for each application; common starting points are 1:500–1:2000 for WB, 1:50–1:200 for IHC-P, and 1:50–1:200 for IF/ICC, though exact concentrations must be determined empirically.
• Cross-reactivity with mouse and rat enables translational studies, but species-specific reactivity should be confirmed using relevant control samples.
• Include negative controls (e.g., knockout cell lines or blocking peptide) to verify signal specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive IVD raw-material partner, offering validated antibody pairs, optimized polyclonal and monoclonal antibodies, and bulk ancillary reagents to support diagnostic manufacturers and research laboratories. This KIAA1456 antibody empowers investigations into tRNA modification and tumor suppression pathways. From rare target sourcing to technical consulting, CamelBio bridges the gap from concept to clinic, ensuring reliable access to critical raw materials for your assays.